Charles River Laboratories International Inc (NYSE: CRL) is -10.68% lower on its value in year-to-date trading and has touched a low of $150.79 and a high of $275.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CRL stock was last observed hovering at around $167.96 in the last trading session, with the day’s loss setting it -3.08%.
Currently trading at $164.88, the stock is 1.78% and -4.45% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.8 million and changing -1.83% at the moment leaves the stock -16.18% off its SMA200. CRL registered -33.93% loss for a year compared to 6-month loss of -19.41%.
The stock witnessed a 0.76% gain in the last 1 month and extending the period to 3 months gives it a -15.78%, and is 1.62% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.19% over the week and 3.10% over the month.
Charles River Laboratories International Inc (CRL) has around 20100 employees, a market worth around $8.43B and $4.05B in sales. Current P/E ratio is 642.81 and Fwd P/E is 15.90. Profit margin for the company is 0.39%. Distance from 52-week low is 9.34% and -40.04% from its 52-week high. The company has generated returns on investments over the last 12 months (0.26%).
with sales reaching $940.5M over the same period.The EPS is expected to shrink by -8.80% this year, but quarterly earnings will post -5.54% year-over-year. Quarterly sales are estimated to shrink -7.02% in year-over-year returns.
The shares outstanding are 51.14M, and float is at 50.57M with Short Float at 4.59%.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 6.1 million shares valued at $1.26 billion. The investor’s holdings represent 11.8396 of the CRL Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.09 million shares valued at $1.05 billion to account for 9.8699 of the shares outstanding. The other top investors are STATE STREET CORP which holds 2.09 million shares representing 4.052 and valued at over $431.52 million, while KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC holds 3.7031 of the shares totaling 1.91 million with a market value of $394.36 million.
Charles River Laboratories International Inc (CRL) Insider Activity
The most recent transaction is an insider purchase by FOSTER JAMES C, the company’s Chairman, President and CEO. SEC filings show that FOSTER JAMES C bought 6,075 shares of the company’s common stock on Feb 20 ’25 at a price of $165.01 per share for a total of $1.0 million. Following the purchase, the insider now owns 0.18 million shares.
Charles River Laboratories International Inc disclosed in a document filed with the SEC on Feb 20 ’25 that Girshick Birgit (Corporate Executive VP & COO) bought a total of 1,514 shares of the company’s common stock. The trade occurred on Feb 20 ’25 and was made at $164.63 per share for $0.25 million. Following the transaction, the insider now directly holds 55058.0 shares of the CRL stock.
Still, SEC filings show that on Feb 20 ’25, LaPlume Joseph W (EVP, Corp Strategy & Develop) disposed off 4,400 shares at an average price of $162.50 for $0.71 million. The insider now directly holds 20,013 shares of Charles River Laboratories International Inc (CRL).
